Results 171 to 180 of about 2,243,647 (283)

Cancer cell‐intrinsic type 1 interferon: production, signaling, and outcomes within sex‐biased, female malignancies

Molecular Oncology, Volume 20, Issue 9, Page 2135-2162, September 2026.
The cell‐autonomous roles of interferon type 1 vary based on duration and intensity. While acute, robust signaling results in cancer cell cytotoxic effects, sustained, low‐level signaling is associated with tumor‐promoting effects. This review summarizes current research of IFN‐1 in cancer and within the clinical setting, with an emphasis on female ...
Ashlyn Conant, Nora Badiner, Sharon Asariah, Kiera McGivney, Vishwa Shah, Tise Suzuki, Yevgeniya J. Ioffe, Juli J. Unternaehrer   +7 more
wiley   +1 more source

Gemcitabine-induced β4 integrin drives cancer progression and gemcitabine resistance in pancreatic cancer. [PDF]

J Exp Clin Cancer Res
Kariya Y, Suzuki H, Kariya Y, Nishita M.
europepmc   +1 more source

Overcoming Photodynamic Therapy Resistance: GSH‐Responsive AIE Photosensitizer‐Hydroxycamptothecin Nanoliposomes for Extrahepatic Cholangiocarcinoma

Advanced Healthcare Materials, Volume 15, Issue 35, 18 September 2026.
A GSH‐responsive AIE nanoplatform (TSH NPs) with RGD‐mediated tumor targeting co‐delivers a photosensitizer (TPA) and HCPT for extrahepatic cholangiocarcinoma. The system synergistically enhances PDT and chemotherapy by suppressing HIF‐1α/VEGF‐driven hypoxic adaptation, effectively overcoming PDT resistance.
Yong Qu, Tao Peng, Yating Zhang, Juanmei Cao, Birong Wang, Chuxing Chai, Zhiyuan Gao, Yiting Xu, Yifan Jin, Yuqing Wang, Zhuoxia Li, Xu Liu, Tianqi Zhao, Yufan Chen, Weimin Lv, Di Lu, Changzheng Huang, Dan Ding, Jinxiang Zhang, Min Li   +19 more
wiley   +1 more source

RBM10 Deficiency Promotes Anti‐PD‐1 Resistance in LUAD via STING Alternative Splicing‐Driven CCL7 Signaling and Macrophage Polarization

Advanced Science, Volume 13, Issue 49, 3 September 2026.
RBM10 deficiency promotes anti‐PD‐1 resistance in lung adenocarcinoma by altering STING alternative splicing, which enhances CCL7 secretion and CCR2‐dependent M2 macrophage polarization. A positive feedback loop via mitochondrial transfer sustains this immunosuppression.
Weitong Gao, Ruqiong Wang, Bo An, Lishuang Qi, Zihan Jing, Xingmei Ren, Yang Zhou, Mingjun Xu, Jiaojiao Li, Jie Liu, Liying Wang, Gang Xu, Rou Li, Dexin Jia, Yan Yu   +14 more
wiley   +1 more source

Combination of hydroxyurea and tranilast suppresses gemcitabine resistance induced by ribonucleotide reductase M1 in gemcitabine-resistant cells

Combination of hydroxyurea and tranilast suppresses gemcitabine resistance induced by ribonucleotide reductase M1 in gemcitabine-resistant cells
博士論文要旨, 最終試験結果の要旨 ...
openaire   +1 more source

ENO1-mediated deoxycytidine synthesis and gemcitabine resistance by stabilizing RRM2 in pancreatic cancer. [PDF]

Cell Death Dis
Li Y, Wang H, Chen L, Gong Y, Zheng D, Li F, Wu C, He Z, Yu C.   +8 more
europepmc   +1 more source

DHODH Drives Sunitinib Resistance Via a Non‐Enzymatic Mechanism by Inhibiting TRIM28 Ubiquitination and Consequent VEGFA Activation in RCC

Advanced Science, Volume 13, Issue 52, 18 September 2026.
This non‑enzymatic function of DHODH drives sunitinib resistance by competing with TRIM37 to block TRIM28 ubiquitination, thereby stabilizing TRIM28 and activating VEGFA transcription. Disrupting the DHODH–TRIM28 interaction with lisaftoclax restores drug sensitivity.
Shijie Qian, Shihang Pu, Zhipeng Xu, Yiheng Ding, Ling Jin, Baochao Li, Qi Li, Xiaohai Xi, Zengjun Wang, Jiajun Xing, Aiming Xu   +10 more
wiley   +1 more source

Targeting IRF7 to overcome gemcitabine resistance in pancreatic ductal adenocarcinoma. [PDF]

iScience
Yang GH, Yan HQ, Lu ZY, Xu QH, Wang Z, Zhao S.   +5 more
europepmc   +1 more source

PARP Inhibitors plus Anlotinib as Bridging Therapy for Armored CAR‐T Cells in Ovarian Cancer Enhances Infiltration and Antitumor Efficacy

Advanced Science, Volume 13, Issue 53, 24 September 2026.
This study shows that a PARP inhibitor combined with anlotinib, administered as bridging therapy, preconditions the tumor microenvironment to enhance the infiltration and antitumor activity of subsequently infused CAR‐T cells across preclinical ovarian cancer models, supporting bridging therapy as a promising strategy to address limited CAR‐T cell ...
Huayi Li, Minghua Xiang, Qiuyang Xu, Jiahao Liu, Xiaofei Jiao, Wei Mu, Xiaoying Lv, Kangjia Tao, Yu Xu, Dongchen Zhou, Wenjian Gong, Danmei Yan, Yixin Hu, Sen Xu, Bingbing Zhao, Jundong Li, Yongkang Gai, Guang Hu, Li Zhu, Qinglei Gao, Yong Fang   +20 more
wiley   +1 more source

Extracellular Vesicle-Mediated Regulation of H3C14 Contributes to Gemcitabine Resistance in Bladder Cancer. [PDF]

J Extracell Vesicles
Huang CS, Yu DS, Jiang SS, Wu YS, Ho JY, Yu CP.   +5 more
europepmc   +1 more source